Smart health technologies have transformed diabetes management. Devices such as continuous glucose monitors (CGMs), insulin pumps, hybrid closed-loop systems, and mobile health applications now generate real-time data that can improve clinical outcomes and quality of life. But the same technologies that empower patients also create new legal and regulatory risks. Without robust protections, sensitive health data can be misused, access to beneficial devices can be denied, and vulnerable populations can face discrimination. This article examines the key legal frameworks that protect diabetics in the development and use of smart health technologies, highlights ongoing challenges, and explores emerging initiatives aimed at ensuring these tools remain safe, equitable, and trustworthy.

The most immediate legal concern for diabetics using connected devices is the security of their personal health information. Smart health technologies collect, transmit, and store highly sensitive data: blood glucose readings, insulin doses, meal logs, physical activity patterns, and even location data. Unauthorized access or disclosure can lead to identity theft, insurance discrimination, or psychological harm. Three principal legal regimes govern this area: the European Union's General Data Protection Regulation (GDPR), the United States' Health Insurance Portability and Accountability Act (HIPAA), and a patchwork of state and sector-specific laws.

General Data Protection Regulation (GDPR)

The GDPR applies to any controller or processor handling the personal data of individuals in the EU, regardless of where the company is based. Health data is classified as a special category under Article 9, requiring explicit consent or another narrow legal basis for processing. For diabetics using an app or device, this means the manufacturer must obtain clear, granular permission before collecting glucose readings or other health metrics. The GDPR also grants individuals strong rights, including the right to access their data, the right to erasure (“right to be forgotten”), and the right to data portability. Companies must implement data protection by design and by default, conduct Data Protection Impact Assessments when introducing new health technologies, and report data breaches within 72 hours. Non-compliance can result in fines of up to 4% of global annual turnover or €20 million, whichever is higher.

HIPAA and the HITECH Act

In the United States, HIPAA sets privacy and security standards for health information held by “covered entities” (healthcare providers, health plans, and healthcare clearinghouses) and their business associates. Many diabetes device manufacturers, app developers, and cloud service providers qualify as business associates if they handle protected health information (PHI) on behalf of a covered entity. HIPAA’s Privacy Rule limits the use and disclosure of PHI to treatment, payment, and healthcare operations, while the Security Rule requires administrative, physical, and technical safeguards for electronic PHI. The HITECH Act strengthened these provisions by expanding enforcement to business associates directly and increasing penalties. For a diabetic whose data is processed by a hospital’s CGM platform, HIPAA provides a baseline of protection — but it does not cover data collected by a consumer-only wellness app that is not connected to a healthcare provider. This gap has become increasingly significant as more patients use direct-to-consumer devices.

U.S. State Laws and the Patchwork Problem

To fill gaps left by HIPAA, states have enacted their own privacy laws. The California Consumer Privacy Act (CCPA) and its amendment, the CPRA, give residents rights over their personal information, including health data not covered by HIPAA. Washington State’s My Health My Data Act goes further, establishing broad protections for consumer health data and creating a private right of action. For a diabetic in California using a smart insulin pen that sends data to a cloud service, the CCPA requires that company to disclose what data is collected, allow opt-out of sale, and honor deletion requests. The patchwork of state laws creates compliance challenges for device manufacturers operating nationally and may lead to inconsistent protections for patients. Federal legislators have proposed a national consumer health data privacy law, but none has passed as of early 2025.

Data Breach Responsibilities

Data breaches involving health devices can expose diabetics to serious harm. If a CGM manufacturer’s cloud database is breached, attackers may gain access to a patient’s glucose trends, insulin dosing history, and personal identifiers. Under both GDPR and HIPAA, entities must notify affected individuals and regulators. Some states have additional notification requirements and may impose civil penalties. The FTC also has authority to bring enforcement actions under Section 5 of the FTC Act against companies that fail to provide reasonable data security. In 2023, the FTC settled with a fertility app developer for deceiving users about data sharing, a case that signals increasing scrutiny on digital health products. Diabetics should be aware that legal protections extend beyond privacy laws to include tort claims for negligence or invasion of privacy when a company fails to safeguard their data.

Accessibility, Non-Discrimination, and Civil Rights

Legal protections for diabetics also focus on ensuring that these individuals are not excluded or disadvantaged because of their condition or the technologies they rely on. Two key federal laws in the United States — the Americans with Disabilities Act (ADA) and the Affordable Care Act (ACA) — play central roles, along with case law on reasonable accommodations and insurance discrimination.

The Americans with Disabilities Act and Diabetes

The ADA defines disability as a physical or mental impairment that substantially limits one or more major life activities. Diabetes, particularly when managed with insulin or monitoring devices, is almost always considered a disability under the ADA. This means employers must provide reasonable accommodations to employees with diabetes, such as allowing time for blood glucose checks, storing insulin or glucose tablets, and permitting flexible break schedules. In the context of smart health technologies, an employer may need to allow a diabetic employee to use a CGM receiver or smartphone app during work hours, even if such devices are otherwise restricted. Failure to do so can constitute unlawful discrimination. Similarly, public accommodations — including stores, restaurants, gyms, and health clubs — must allow diabetics to carry and use their devices. The Department of Justice has issued guidance enforcing the ADA in digital spaces, which may extend to the accessibility of mobile health apps for users with diabetes-related vision or motor impairments.

Employment and Insurance Discrimination

Beyond the ADA, the Genetic Information Nondiscrimination Act (GINA) and the ACA provide additional safeguards. GINA prohibits employers and health insurers from using genetic information — which can include family history of diabetes — to make employment decisions or set insurance premiums. The ACA prohibits exclusions for pre-existing conditions, meaning diabetics cannot be denied health insurance coverage because of their diagnosis. This is critical for access to smart health technologies, as many insurers now cover CGMs, insulin pumps, and associated supplies. The ACA also requires non-discrimination based on health status in health plan enrollment and pricing. However, insurers may still impose higher cost-sharing or require step therapy before covering a particular device, which can create financial barriers for diabetics who need the newest technology.

Discrimination by Device Algorithms

An emerging civil rights concern is algorithmic bias in smart health technologies. If a CGM or insulin dose recommendation algorithm is trained on data from a predominantly white, high-income population, it may produce less accurate results for other demographic groups. The ADA and other anti-discrimination laws have not yet been clearly applied to such algorithmic bias, but the Department of Health and Human Services likely has authority under Section 1557 of the ACA to address discrimination in health programs and activities that receive federal funding. In 2024, HHS issued a proposed rule requiring covered entities to evaluate their use of algorithms for discriminatory effects. For diabetics, this could mean that manufacturers and healthcare providers must test the performance of their smart health tools across different races, ethnicities, and socio-economic groups before deploying them widely.

Regulatory Oversight for Device Safety and Efficacy

Smart health technologies for diabetes are often medical devices subject to premarket review and post-market surveillance. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the primary regulators, with the European Union’s Medical Device Regulation (MDR) also relevant.

FDA Classification and Approval Pathways

The FDA regulates diabetes devices under the Federal Food, Drug, and Cosmetic Act. Most CGMs and insulin pumps are Class II devices subject to 510(k) premarket notification, meaning the manufacturer must demonstrate substantial equivalence to a predicate device. Hybrid closed-loop systems (the “artificial pancreas”) are Class III devices requiring more rigorous premarket approval (PMA) with clinical studies. The FDA has also developed expedited pathways, such as the Breakthrough Devices Program, to accelerate development of novel diabetes technologies. Legal protections for diabetics arise from the premarket review process, which must ensure that the device is safe and effective for its intended use. If a manufacturer receives clearance based on a flawed predicate or fails to report adverse events, the FDA can require recall or impose penalties.

Software as a Medical Device (SaMD)

Many diabetes apps and decision-support tools are classified as Software as a Medical Device (SaMD). The FDA has issued guidance on clinical evaluation of SaMD, and the International Medical Device Regulators Forum (IMDRF) has developed risk-based categories. A standalone app that calculates insulin doses based on glucose readings and patient inputs is a higher-risk SaMD and warrants more regulatory scrutiny than a simple logbook app. The recent FDA update to its Digital Health Policy (2024) clarifies that certain low-risk general wellness products are not regulated, but any product that makes a specific clinical recommendation or drives treatment decisions likely falls under device regulation. Manufacturers must ensure their SaMD is validated, maintained with updates, and subject to cybersecurity monitoring. Diabetics benefit from knowing that every algorithm affecting their dosing has undergone some level of regulatory review.

Post-Market Surveillance and Adverse Event Reporting

Even after a device is cleared or approved, legal obligations continue. Manufacturers must monitor for safety signals and report adverse events to the FDA through the Medical Device Reporting (MDR) process. For a diabetic using a pump that unexpectedly delivers an incorrect basal rate, the manufacturer must investigate and may be required to issue a field safety corrective action or recall. The FDA’s Sentinel Initiative leverages real-world data to identify potential device problems faster. The legal framework also allows patients to file individual tort claims (product liability) if they suffer harm due to a defective device. Class action lawsuits have been filed against CGM manufacturers for alleged inaccuracies leading to hypoglycemic events. These product liability cases are a critical backstop when regulatory oversight fails, and they drive manufacturers to invest in better quality and transparency.

Despite the comprehensive protections outlined above, significant gaps and tensions remain. The rapid pace of innovation often outstrips the ability of regulators and lawmakers to keep up.

Lack of Harmonization Across Jurisdictions

A diabetic who travels between the EU and the US may face inconsistent privacy and device safety protections. GDPR bars the transfer of health data to countries without adequate protections, while US law may not recognize the same rights. A US-based CGM manufacturer that processes data in the cloud may need to rely on Standard Contractual Clauses (SCCs) for EU users, but the legal viability of those clauses has been challenged. Similarly, the EU MDR imposes stricter requirements for clinical evidence and annual re-certification than the FDA’s 510(k) process, creating potential delays in bringing devices to European markets. For patients, this can mean that a cutting-edge device available in one country is not accessible in another, or that their data rights vanish when they cross a border.

AI and Algorithmic Bias

The use of artificial intelligence in diabetes devices — from predictive algorithms to automated insulin delivery — introduces new legal risks. The FDA has not yet established a comprehensive framework for validating AI models that can change over time (adaptive algorithms). If an algorithm is trained on biased data, it may be less accurate for minorities, women, or people with type 1 vs. type 2 diabetes. Currently, no specific federal law prohibits such bias in medical devices, though the FDA may deny clearance if the algorithm’s performance is inconsistent across subgroups. The FTC could also pursue deceptive trade practice claims if a company markets a device as effective for all populations without adequate testing. Diabetics should be aware that algorithmic bias can exacerbate health disparities, and they have a right to ask their provider whether a particular device has been validated for their demographic.

Smart health technologies generate a constant stream of data, some of which may be repurposed beyond the original clinical intent. A patient may consent to having their glucose data used for device improvement but later find it shared with a pharmaceutical company for marketing. The traditional informed consent model — a one-time form signed at the doctor’s office — is poorly suited to the dynamic environment of digital health. The GDPR’s explicit consent requirement is stronger, but many mobile apps still bury privacy policies in dense text. The FDA has encouraged manufacturers to provide clear, layered consent notices, and the Office for Civil Rights (OCR) under HIPAA has issued guidance on patient authorization for electronic PHI. However, enforcement remains sporadic. Diabetics should be proactive: ask what data is collected, how it is used, and how long it is retained. They have a legal right to be informed, regardless of which law applies.

Policymakers, regulators, and industry groups are actively working to address these challenges. Several initiatives promise to reshape the legal landscape for diabetics using smart health technologies.

The EU AI Act and Medical Algorithms

The European Union’s AI Act, expected to be fully enforced in 2026, classifies health-related AI systems as high-risk. This includes any AI used in medical devices or for patient management. High-risk AI systems will be subject to strict requirements for data governance, transparency, human oversight, and accuracy. For diabetes devices, this means manufacturers must log and report incidents, conduct conformity assessments, and allow users to override automated decisions. The AI Act also prohibits certain uses of biometric categorization, which could affect devices that use facial recognition or emotional analysis (unlikely in diabetes, but not impossible). This regulation could become a global benchmark, much like GDPR.

Global Data Protection Standards and Interoperability

Efforts to build a global framework for health data protection are ongoing. The Global Alliance for Genomics and Health (GA4GH) has developed data-sharing frameworks, and the International Medical Device Regulators Forum (IMDRF) has produced guidance on cybersecurity for SaMD. In the US, the 21st Century Cures Act requires health IT systems to support interoperability, including the use of standardized APIs. This allows diabetics to access their device data through the app or portal of their choice, reducing vendor lock-in. The Information Blocking Rule prohibits providers from interfering with patient access to their electronic health information. For diabetics, interoperability means they can share their CGM data with a nutrition app or a telehealth platform without losing control. Legal challenges arise when companies assert intellectual property rights over data formats, but regulators are pushing for openness.

Patient Empowerment and Data Ownership

An emerging legal concept is that of data ownership or a fiduciary duty owed by health tech companies to users. Some legal scholars argue that patients should own their health data, with the right to license it to companies under transparent terms. Several startups now offer “data trusts” or “personal health data wallets” that give diabetics granular control over who accesses their glucose readings. While not yet enshrined in law, the patient empowerment movement is influencing regulation. The GDPR’s data portability right is the clearest legal expression: a diabetic can request their CGM data in a machine-readable format and move it to a competing platform. Some state laws, like the Colorado Privacy Act, contain provisions that strengthen this right. Manufacturers that resist portability may face enforcement actions.

Conclusion: A Path Forward for Diabetics and Developers

Legal protections for diabetics using smart health technologies are evolving rapidly, but they remain incomplete. Data privacy laws like GDPR and HIPAA provide a foundation, but gaps remain for consumer-health data and cross-border transfers. Anti-discrimination laws under the ADA and ACA ensure that diabetics are not excluded from jobs or insurance because of their condition or devices, yet algorithmic bias challenges those protections. Strong regulatory oversight by the FDA and EMA helps guarantee device safety, but the pace of innovation demands adaptive approaches. The emerging frameworks — EU AI Act, interoperability mandates, data ownership models — offer hope for a more cohesive, patient-centered system.

For diabetics, the key takeaway is that legal rights exist, but they must be exercised. Patients should read privacy policies, ask their clinicians about device validation across demographics, and file complaints with regulators if they experience discrimination or data misuse. For developers and manufacturers, compliance is not simply a legal obligation — it is a competitive advantage. Building trust through transparent data practices, inclusive algorithm design, and rigorous safety testing will ultimately drive adoption and improve outcomes. As smart health technologies become more deeply integrated into daily diabetes care, the legal framework must continue to adapt, ensuring that innovation serves patients without compromising their rights.